The Transcriptional Co-Activator cAMP Response Element-Binding Protein-Binding Protein Is Expressed in Prostate Cancer and Enhances Androgen- and Anti-Androgen-Induced Androgen Receptor Function
January 2003
in “
American Journal of Pathology
”
New to Bicalutamide? There is a guide in the encyclopedia. Read the guide → 
Studysummary This study found that the co-activator CBP enhances the agonistic action of hydroxyflutamide on androgen receptors, suggesting a mechanism for therapy resistance in prostate cancer.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The 2002 study investigated the role of the transcriptional co-activator cAMP Response Element-Binding Protein-Binding Protein (CBP) in prostate cancer. Researchers found that CBP was expressed in all prostate cancer cell lines tested (LNCaP, PC-3, and DU-145), and its overexpression influenced the balance of nonsteroidal anti-androgens, enhancing their agonistic properties. CBP was also found in benign, premalignant, and malignant prostate tissues from patients, but its expression was lost in three primary tumors and in 2 of 26 lymph node metastases. The study suggested that CBP could play a role in the progression of prostate cancer and the effectiveness of anti-androgen therapies. However, other androgen receptor co-activators might account for diminished antagonism of bicalutamide, indicating a need for further research.
